Usefulness of a new immunoradiometric assay of HCV core antigen to predict virological response during PEG-IFN/RBV combination therapy for chronic hepatitis with high viral load of serum HCV RNA genotype 1b

Intervirology

Volumn 51, Issue SUPPL. 1, 2008, Pages 70-75

  Sasase, Noriko ^a   Kim, Soo Ryang ^a   Kim, Ke Ih ^a   Taniguchi, Miyuki ^a   Imoto, Susumu ^a   Mita, Keiji ^a   Hotta, Hak ^b   Shouji, Ikuo ^b   El Shamy, Ahmed ^b   Kawada, Norifumi ^c   Kudo, Masatoshi ^d   Hayashi, Yoshitake ^b  

^a KOBE ASAHI HOSPITAL   (Japan)

^b KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Chronic hepatitis; HCV core antigen; HCV RNA genotype 1b; Immunoradiometric assay; PEG IFN RBV combination therapy; Prediction, virological response

Indexed keywords

HEPATITIS C CORE ANTIGEN; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS ANTIGEN; VIRUS RNA;

CHRONIC HEPATITIS; CLINICAL ARTICLE; CONFERENCE PAPER; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNORADIOMETRIC ASSAY; PREDICTION; PRIORITY JOURNAL; THERAPY RESISTANCE; VIRUS INHIBITION; VIRUS LOAD;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS C ANTIGENS; HEPATITIS C, CHRONIC; HUMANS; IMMUNORADIOMETRIC ASSAY; INTERFERON ALFA-2B; PROGNOSIS; RIBAVIRIN; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; VIRAL CORE PROTEINS; VIRAL LOAD;

HEPATITIS C VIRUS;

EID: 44949144917     PISSN: 03005526     EISSN: None     Source Type: Journal    
DOI: 10.1159/000122601     Document Type: Conference Paper

References (21)

1. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;26:975-982.
2. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: randomized trial. Lancet 2001;22:958-965.
3. Nakamura H: Early prediction of sustained viral responder and non-responder during interferon and ribavirin combination therapy in chronic hepatitis C. Hepatol Res 2005;33:269-271.
4. El-Shamy A, Sasayama M, Nagano-Fujii M, Sasase N, Imoto S, Kim SR, Hotta H: Prediction of efficient virological response to pegylated interferon/ribavirin combination therapy by NS5A sequences of hepatitis C virus and anti-NS5A antibodies in pre-treatment sera. Microbiol Immunol 2007;51:471-482.
5. Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, Ogura Y, Izumi N, Marumo F, Sato C: Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 1996;334:77-81.
6. Akuta N, Suzuki S, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Arase Y, Ikeda K, Miyakawa Y, Kumada H: Prediction of response to pegylated interferon and ribavirin in hepatitis C by polymorphism in the viral core protein and very early dynamics of viremia. Intervirology 2007;50:361-368.
7. Ferenci P: Predictors of response to therapy for chronic hepatitis C. Semin Liver Dis 2004;24:S25-S31.
8. Dickson RC, Mizokami M, Orito E, Qian KP, Lau JY: Quantification of serum HCV core antigen by a fluorescent enzyme immunoassay in liver transplant recipients with recurrent hepatitis C - clinical and virologic implications. Transplantation 1999;68:1512-1516.
9. Komatsu F, Takahashi K: Determination of serum hepatitis C (HCV) core protein using a novel approach for quantitative evaluation of HCV viremia in anti-HCV-positive patients. Liver 1999;19:375-380.
10. Widell A, Molnegren V, Pieksma F, Calmann M, Peterson J, Lee SR: Detection of hepatitis C core antigen in serum or plasma as a marker of hepatitis C viremia in the serological window-phase. Transfus Med 2002;12:107-113.
11. Aoyagi K, Ohue C, Iida K, Kimura T, Tanaka E, Kiyosawa K, Yagi S: Development of a simple and highly sensitive enzyme immunoassay for hepatitis C virus core antigen. J Clin Microbiol 1999;37:1802-1808.
12. Hayashi K, Hasuike S, Kusumoto K, Ido A, Uto H, Kenji N, Kohara M, Stuver SO: Usefulness of a new immuno-radiometric assay to detect hepatitis C core antigen in a community-based population. J Viral Hepat 2005;12:106-110.
13. Tanaka T, Lau JYN, Mizokami M, Orito E, Tanaka E, Kiyosawa K, Yasui K, Ohta Y, Hasegawa A, Tanaka S, et al: Simple fluorescent enzyme immunoassay for detection and quantification of hepatitis C viremia. J Hepatol 1995;23:742-745.
14. Tanaka E, Ohue C, Aoyagi K, Yamaguchi K, Yagi S, Kiyosawa K, Alter HJ: Evaluation of a new enzyme immunoassay for hepatitis C virus (HCV) core antigen with clinical sensitivity approximating that of genomic amplification of HCV RNA. Hepatology 2000;32:388-393.
15. Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J: Early virologic response to treatment with peginterferon alfa 2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003;38:645-652.
16. Davis GL: Monitoring of viral levels during therapy of hepatitis C. Hepatology 2002;36:S145-S151.
17. Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, Perelson AS: Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-α therapy. Science 1998;282:103-107.
18. Lam NP, Neumann AU, Gretch DR, Wiley TE, Perelson AS, Layden TJ: Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa. Hepatology 1997;26:226-231.
19. Zeuzem S, Herrmann E, Lee JH, Fricke J, Neumann AU, Modi M, Colucci G, Roth WK: Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alfa-2a. Gastroenterology 2001;120:1438-1447.
20. Buti M, Valdes A, Sanchez-Avila F, Esteban R, Lurie Y: Extending combination therapy with peginterferon alfa-2b plus ribavirin for genotype 1 chronic hepatitis C late responders: a report of 9 cases. Hepatology 2003;37:1226-1227.
21. Berg T, von Wagner M, Nasser S, Sarrazin C, Heintges T, Gerlach T, Buggisch P, Goeser T, Rasenack J, Pape GR, Schmidt WE, Kallinowski B, Klinker H, Spingler U, Martus P, Alshuth U, Zeuzem S: Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 2006;130:1086-1097.